XML 58 R13.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Note 1 - Significant Accounting Policies (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Notes Tables |
Debt Securities, Available-for-sale [Table Text Block] |
|  | September 30, 2018
|  | Amortized Cost |  | Accrued Interest |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Obligations of the U.S. Government and its agencies |  | $ | 51,436 |  |  | $ | 170 |  |  | $ | — |  |  | $ | (188 | ) |  | $ | 51,418 |
Corporate debt securities |  |  | 40,893 |  |  |  | 244 |  |  |  | — |  |  |  | (207 | ) |  |  | 40,930 |
Certificates of deposit |  |  | 4,543 |  |  |  | 18 |  |  |  | — |  |  |  | (15 | ) |  |  | 4,546 |
Total investments |  | $ | 96,872 |  |  | $ | 432 |  |  | $ | — |  |  | $ | (410 | ) |  | $ | 96,894 |
|  | December 31, 2017
|  | Amortized Cost |  | Accrued Interest |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Obligations of the U.S. Government and its agencies |  | $ | 60,121 |  |  | $ | 177 |  |  | $ | — |  |  | $ | (122 | ) |  | $ | 60,176 |
Corporate debt securities |  |  | 34,021 |  |  |  | 203 |  |  |  | — |  |  |  | (108 | ) |  |  | 34,116 |
Certificates of deposit |  |  | 11,099 |  |  |  | 32 |  |  |  | 1 |  |  |  | (14 | ) |  |  | 11,118 |
Total investments |  | $ | 105,241 |  |  | $ | 412 |  |  | $ | 1 |  |  | $ | (244 | ) |  | $ | 105,410 |
Available For Sale Securities Debt Maturities Fair Value [Table Text Block] |
|  | 2018 |  | 2017
Maturing in one year or less |  | $ | 67,737 |  |  | $ | 64,115 |
Maturing after one year through two years |  |  | 29,157 |  |  |  | 34,257 |
Maturing after two years |  |  | — |  |  |  | 7,038 |
Total investments |  | $ | 96,894 |  |  | $ | 105,410 |
Schedule of Receivables from Collaborations [Table Text Block] |
|  | September 30, 2018
|  | Billed |  | Unbilled |  | Total
U.S. Department of Health and Human Services |  | $ | 403 |  |  | $ | 1,289 |  |  | $ | 1,692 |
Shionogi & Co. Ltd. |  |  | 35 |  |  |  | — |  |  |  | 35 |
Green Cross Corporation |  |  | 313 |  |  |  | 27 |  |  |  | 340 |
Mundipharma International Holdings Limited |  |  | 75 |  |  |  | — |  |  |  | 75 |
Seqirus UK Limited |  |  | 1,252 |  |  |  | — |  |  |  | 1,252 |
Total receivables |  | $ | 2,078 |  |  | $ | 1,316 |  |  | $ | 3,394 |
|  | December 31, 2017
|  | Billed |  | Unbilled |  | Total
U.S. Department of Health and Human Services |  | $ | 42 |  |  | $ | 2,020 |  |  | $ | 2,062 |
Shionogi & Co. Ltd. |  |  | 1,600 |  |  |  | — |  |  |  | 1,600 |
Green Cross Corporation |  |  | 1,388 |  |  |  | 28 |  |  |  | 1,416 |
Mundipharma International Holdings Limited |  |  | 47 |  |  |  | — |  |  |  | 47 |
Seqirus UK Limited |  |  | 825 |  |  |  | 167 |  |  |  | 992 |
Total receivables |  | $ | 3,902 |  |  | $ | 2,215 |  |  | $ | 6,117 |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] |
|  | Balance at December 31, 2017 |  | Adjustments due to ASC 606 |  | Balance at January 1, 2018
Assets |  |  |  |  |  |  |  |  |  |  |  |
Deferred collaboration expense |  | $ | 210 |  |  | $ | (58 | ) |  | $ | 152 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 8,484 |  |  | $ | (1,184 | ) |  | $ | 7,300 |
Equity |  |  |  |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | (631,843 | ) |  | $ | 1,126 |  |  | $ | (630,717 | )
|  | September 30, 2018
|  | As Reported |  | Adjustments due to ASC 606 |  | Balances without adoption of ASC 606
Assets |  |  |  |  |  |
Deferred collaboration expense |  | $ | 8 |  |  | $ | 19 |  |  | $ | 27 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 200 |  |  | $ | 396 |  |  | $ | 596 |
Equity |  |  |  |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | (704,537 | ) |  | $ | 378 |  |  | $ | (704,159 | )
|  | For the Three Months Ended September 30, 2018
|  | As Reported |  | Adjustments due to ASC 606 |  | Balances without adoption of ASC 606
Collaborative and other research and development revenue |  | $ | 931 |  |  | $ | 296 |  |  | $ | 1,227 |
Research and development expenses |  |  | 22,006 |  |  |  | 14 |  |  |  | 22,021 |
Net loss |  |  | (29,597 | ) |  |  | 282 |  |  |  | (29,315 | )
Basic and diluted net loss per share |  | $ | (0.28 | ) |  | $ | 0.00 |  |  | $ | (0.28 | )
|  | For the Nine Months Ended September 30, 2018
|  | As Reported |  | Adjustments due to ASC 606 |  | Balances without adoption of ASC 606
Collaborative and other research and development revenue |  | $ | 13,598 |  |  | $ | 888 |  |  | $ | 14,486 |
Research and development expenses |  |  | 61,457 |  |  |  | 44 |  |  |  | 61,501 |
Net loss |  |  | (73,820 | ) |  |  | 846 |  |  |  | (72,974 | )
Basic and diluted net loss per share |  | $ | (0.73 | ) |  | $ | 0.01 |  |  | $ | (0.72 | )
Disaggregation of Revenue [Table Text Block] |
|  | Three Months |  | Nine Months
|  | 2018 |  | 2017 |  | 2018 |  | 2017
Product sales |  | $ | — |  |  | $ | 1,501 |  |  | $ | — |  |  | $ | 1,501 |
Royalty revenue |  |  | 523 |  |  |  | 442 |  |  |  | 4,326 |  |  |  | 7,252 |
Collaborative and other research and development revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. Department of Health and Human Services |  |  | 931 |  |  |  | 1,490 |  |  |  | 1,598 |  |  |  | 4,305 |
Shionogi & Co. Ltd. |  |  | — |  |  |  | 296 |  |  |  | — |  |  |  | 888 |
Seqirus UK Limited |  |  | — |  |  |  | 5,031 |  |  |  | 12,000 |  |  |  | 7,350 |
Total collaborative and other research and development revenues |  |  | 931 |  |  |  | 6,817 |  |  |  | 13,598 |  |  |  | 12,543 |
Total revenues |  | $ | 1,454 |  |  | $ | 8,760 |  |  | $ | 17,924 |  |  | $ | 21,296 |

X
- Definition Tabular disclosure of available for sale securities debt maturities fair value. + References No definition available. + Details
Name: | bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock
Namespace Prefix: | bcrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure representing receivables from collaborations. + References No definition available. + Details
Name: | bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock
Namespace Prefix: | bcrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 + Details
Name: | us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.10-01.(b)(6)) -URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 + Details
Name: | us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration